Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Nicotinic acetylcholine receptor partial agonist (plant-derived alkaloid) -- smoking-cessation aid

Cytisine

Cravv

Dosage form
Tablet
Available strengths
1.5 mg
Drug class
Nicotinic acetylcholine receptor partial agonist (plant-derived alkaloid) -- smoking-cessation aid
Common brand
Cravv

Clinical overview. Cytisine (Cravv) is a plant-derived, non-prescription nicotinic acetylcholine receptor partial agonist licensed in Canada as a natural health product for smoking cessation. It shares its mechanism with varenicline and is taken on a tapering 25-day dosing course (or an alternative 3 mg three-times-daily, 12-week regimen), with a target quit date on day 5 of the traditional schedule.

Indication

Common therapeutic uses

  • Licensed in Canada as a natural health product to assist with smoking cessation, used as an aid to reduce nicotine cravings and withdrawal symptoms during a quit attempt.
  • Available without a prescription.

Pregnancy

Risk assessment and monitoring considerations

  • Safety in pregnancy has not been established; behavioural counselling and, if pharmacotherapy is needed, better-studied agents are generally preferred -- discuss with the prescriber before use in pregnancy.

Breastfeeding

Infant exposure considerations

  • Safety during breastfeeding has not been established.

Geriatrics

Dosing and tolerability considerations

  • No specific dose adjustment established; use standard adult dosing.

Pediatrics

Use in children and adolescents

  • Not established for use under 18 years of age.

Dosage & Administration

Practical dosing and administration

  • Traditional 25-day tapering course, started while the patient continues to smoke, with a target quit date on day 5.
  • Days 1-3: 1.5 mg (1 capsule) every 2 hours while awake, up to 6 capsules/day, while gradually reducing cigarette intake.
  • Days 4-12: 1.5 mg (1 capsule) every 2.5 hours, up to 5 capsules/day.
  • Days 13-16: 1.5 mg (1 capsule) every 3 hours, up to 4 capsules/day.
  • Days 17-20: 1.5 mg (1 capsule) every 5 hours, up to 3 capsules/day.
  • Days 21-25: 1.5-3 mg (1-2 capsules)/day, then discontinue.
  • Alternative regimen: 3 mg (2 capsules) 3 times daily for 12 weeks (a less frequent, longer-duration schedule).
  • Take with a full glass of water; avoid taking within 1 hour of eating a large meal.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Nicotinic-receptor-agonist toxicity can occur with excessive doses: nausea, vomiting, headache, dizziness, tachycardia, and, in severe cases, seizures or respiratory depression. Seek medical attention for suspected overdose.

Common side effects

Frequently reported tolerability concerns

  • Gastrointestinal upset, nausea, vomiting.
  • Sleep disturbances, including abnormal dreams.
  • Headache.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Rare reports of mood or behavioural changes; theoretical risk given its shared mechanism with varenicline -- monitor patients with a psychiatric history closely.
  • Seek urgent care for a seizure, severe allergic reaction, or new or worsening suicidal thoughts.

Use with caution

Situations requiring closer assessment

  • Use with caution and closer monitoring in patients with a history of psychiatric disorders.
  • Cardiovascular disease -- data are more limited than for varenicline or NRT; use clinical judgment.

Contraindications

Situations where therapy may be inappropriate

  • Known hypersensitivity to cytisine or any component of the formulation.

Drug interactions

Clinically relevant combinations

  • Combining with varenicline is not recommended, since both act on the same nicotinic receptor pathway.
  • No other clinically significant drug interactions have been established; as with all smoking-cessation therapies, stopping smoking itself (independent of cytisine) can raise serum levels of some CYP1A2-cleared drugs.

Food interactions

Meal-related administration

  • No significant food interaction identified; take with a full glass of water.

Time of administration

Practical scheduling

  • Multiple times daily on a tapering schedule (see Dosage & Administration) -- using a phone alarm or dosing chart to track the changing schedule is recommended.

Storage

Product handling

  • Store at room temperature, out of reach and sight of children.

Patient take-away

Key counselling points for a quick closing summary

  • Follow the exact tapering schedule -- the number of capsules and time between doses changes throughout the 25-day course.
  • Set your quit date for day 5 of treatment, while continuing to gradually cut down beforehand.
  • This product is available without a prescription, but tell your pharmacist you are using it so it can be checked against your other medicines.
  • Seek urgent care for a seizure, a severe allergic reaction, or new or worsening thoughts of self-harm.

References

Source material and product information

  1. Health Canada Licensed Natural Health Products Database -- Cravv (cytisine), NPN 80072525

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.